Whalesbook
Shareholder Shuffle at Cohance Lifesciences: JASUB Group Adjusts Stake
Mumbai, India - In a move requiring disclosure under SEBI's takeover regulations, JASUB Property Holdings LLP and its affiliated Persons Acting in Concert (PACs) have recently adjusted their collective shareholding in Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited). The transactions, executed via inter-se transfers through block deals on February 18, 2026, resulted in a net reduction of the group's aggregate stake in the pharmaceutical contract development and manufacturing organization (CDMO).
The group's total shareholding post-transaction stands at 2,43,26,009 shares, representing 6.36% of Cohance Lifesciences' total equity. This marks a decrease from their prior aggregate holding of 6.59% (2,52,02,957 shares). While JASUB Property Holdings LLP itself acquired 70,00,000 equity shares (1.83% of total capital) in the process, the overall group holding declined, indicating that other PACs within the group sold a larger number of shares than JASUB acquired. This adjustment follows prior open market sales of approximately 8,76,948 shares (0.23%) between September 2025 and January 2026.
The Backstory: Cohance Lifesciences' Evolution and JASUB's Role
Cohance Lifesciences, a prominent player in the global CDMO space, represents a strategic integration of various pharmaceutical entities, including Suven Pharmaceuticals, which itself was carved out from Suven Life Sciences. The company focuses on providing a comprehensive suite of services from drug development to commercial manufacturing for global pharmaceutical and biotech clients. JASUB Property Holdings LLP, an active limited liability partnership established in 2018 and involved in financial services, has had connections with entities linked to the Jasti family, promoters of the original Suven group. This shareholding adjustment, therefore, reflects an internal reallocation or reduction within a significant stakeholder group.
Recent Regulatory Scrutiny and Financials
This shareholding update comes at a time when Cohance Lifesciences is navigating some regulatory challenges. In July 2025, the company settled an alleged violation of foreign exchange rules with the Reserve Bank of India (RBI) by paying a compounding fee of ₹8.30 crore. More recently, in February 2026, Cohance disclosed receiving a warning letter from the US Food and Drug Administration (USFDA) concerning its Hyderabad facility, following an inspection in August 2025. While the facility contributes less than 2% to US revenue, the company has stated its commitment to addressing the FDA's concerns.
Despite these regulatory matters, Cohance Lifesciences recently reported strong financial results for the quarter ending December 2024, achieving record operating profit, profit before tax, and net sales, alongside a peak in earnings per share. However, a decline in its debtors turnover ratio and cash reserves were also noted in the same period.
The 'So What' for Investors
For investors, the inter-se transfer and net reduction in aggregate shareholding by JASUB and its PACs could be interpreted in various ways. It may signify a strategic reallocation of assets within the promoter group or a partial exit. Coupled with recent regulatory disclosures—the US FDA warning and the RBI compounding fee—these developments warrant close observation. While the company has demonstrated recent financial strength, the market will be watching how effectively Cohance Lifesciences addresses the regulatory concerns and manages its operational liquidity.
Peer Comparison
Cohance Lifesciences operates in a competitive CDMO and API landscape, with key rivals including Aurobindo Pharma, Almac Group, Pharmaron, Boehringer Ingelheim, Pfizer, Cipla, and Divi's Laboratories. The performance and strategic moves of these peers, alongside Cohance's ability to manage its operational and regulatory challenges, will be crucial in defining its future trajectory.